Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2021.09.15.21263583: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis Where sample size was very small and VE estimates highly imprecise, estimates are not presented. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:27,28 Limitations: The strengths and limitations of our dataset and an evaluation of vaccine effectiveness using the test negative case control design have been described in …
SciScore for 10.1101/2021.09.15.21263583: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis Where sample size was very small and VE estimates highly imprecise, estimates are not presented. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:27,28 Limitations: The strengths and limitations of our dataset and an evaluation of vaccine effectiveness using the test negative case control design have been described in detail previously.1,6 There are some notable limitations worth highlighting that could particularly affect the interpretation of results on waning. First, there are important differences in the groups that received different vaccines as part of the roll-out of the national programme in the UK. For example, Comirnaty was less likely to be used in care homes and among individuals in clinical risk groups, in particular housebound individuals, due to challenges in ultra-low temperature storage and delivery. Instead, Vaxzevria was more likely to be given to these groups but this vaccine was not given to healthy adults under 40 years of age following a recommendation to use alternative vaccines in this age-group because of the risk of vaccine-induced thrombotic thrombocytopenia.29 While we do adjust for age-group and clinical risk groups in our analysis, this is unlikely to fully mitigate the differences. Second, over time there will be an increasing number of individuals who would have been infected both prior to and after vaccination. Where they have previously tested positive they will be excluded from the analysis, but many will remain unknown. This means that an increasing proportion of the unvaccinated control group may have some level of protection from natural infection. This will attenuate vaccine effe...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-